To gain further insight on the molecular mechanism mediating gMDSC recruitment to BCM-2277 tumors, we then treated a cohort of tumor-bearing mice with an inhibitor of CXCR2, the receptor through which CXCL1 and CXCL2 signal. This evidence concerns the gene CXCL2 and neoplasm.